EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Accelerate Diagnostics's Enterprise Value is $46.17 Mil.
Accelerate Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-41.23 Mil. Therefore, Accelerate Diagnostics's EV-to-FCF for today is -1.12.
The historical rank and industry rank for Accelerate Diagnostics's EV-to-FCF or its related term are showing as below:
AXDX'
s EV-to-FCF Range Over the Past 10 Years
Min: -101.37 Med: -15.02 Max: -0.93
Current: -1.12
During the past 13 years, the highest EV-to-FCF of Accelerate Diagnostics was -0.93. The lowest was -101.37. And the median was -15.02.
AXDX's EV-to-FCF is ranked worse than 100% of 372
companies
in the Medical Devices & Instruments industry
Industry Median: 25.71
vs AXDX: -1.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Accelerate Diagnostics's EV-to-FCF
For the Medical Devices subindustry, Accelerate Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's EV-to-FCF falls into.
Accelerate Diagnostics's current Enterprise Value is $46.17 Mil.
Accelerate Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Accelerate Diagnostics's PE Ratio for today is calculated as:
Accelerate Diagnostics's share price for today is $0.9453.
Accelerate Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Accelerate Diagnostics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Accelerate Diagnostics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Accelerate Diagnostics (Accelerate Diagnostics) Business Description
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AXDX has been successfully added to your 